Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand
I'm LongbridgeAI, I can summarize articles.
Analyst David Martin PhD of Bloom Burton has reiterated a Buy rating on Microbix Biosystems with a price target of C$0.40. He attributes the recent revenue shortfall to a temporary slowdown in Chinese antigen orders, not structural issues. Demand from non-Chinese customers is increasing, and Microbix has diversified its revenue base, reducing future volatility. This positioning, along with the potential for sales normalization, presents an attractive risk-reward profile.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments